The Green Mountain oncology Group/CCOP is a mature regional cooperative group now entering its second decade of promoting clinical trials, cancer prevention and control research and state-of-the-art cancer management throughout most of Vermont. The group is composed of all of the full time community medical and radiation oncologists in Vermont and the surgeons, pathologists, radiologists, primary care physicians, physicians assistants, nurse practitioners, oncology nurses, social workers and psychologists associated with them.
The Specific Aims are to: 1. Continue and expand our commitment to clinical treatment and cancer control research activities in the communities of Vermont in collaboration with the Vermont Cancer Center, the Vermont Department of Health/Vermont Coalition on Cancer Prevention and Control and the Vermont Program for Quality Health Care. 2. Use clinical research as a model for optimal cancer control. 3. Accrue 60 credits annually on cancer treatment protocols as members of the CALGB and NSABP. 4. Accrue 50 cancer control research credits on protocols of the URCC, CALGB and NSABP research bases. 5. Continue to promote the diffusion of state-of-the-art cancer management to primary care physicians by involving them in cancer control projects and through educational programs. The group is made up of four components: The Operations Office at the Rutland Regional Medical Center, Central Vermont Hospital in Berlin, Fanny Allen Hospital in Colchester, and Southwestern Vermont Medical Center in Bennington. The GMOG/CCOP, in collaboration with the Vermont Cancer Center, provides state-of-the-art cancer treatment and clinical research to about 70% of the 562,000 residents of Vermont. The group has memberships in the NSABP and CALGB and the URCC for cancer control research studies. The GMOG has successfully passed all the audits by the research bases and has met accrual goals for treatment protocols. The group has made achievement of the cancer accrual goals a priority for the next grant period.
|Kolitz, Jonathan E; George, Stephen L; Benson Jr, Don M et al. (2014) Recombinant interleukin-2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: results from Cancer and Leukemia Group B 19808. Cancer 120:1010-7|
|Demmy, Todd L; Gu, Lin; Burkhalter, Jack E et al. (2012) Optimal management of malignant pleural effusions (results of CALGB 30102). J Natl Compr Canc Netw 10:975-82|
|Bertagnolli, Monica M; Redston, Mark; Compton, Carolyn C et al. (2011) Microsatellite instability and loss of heterozygosity at chromosomal location 18q: prospective evaluation of biomarkers for stages II and III colon cancer--a study of CALGB 9581 and 89803. J Clin Oncol 29:3153-62|
|Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST) (2010) Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients. J Clin Oncol 28:1247-53|
|Blanke, Charles D; Rankin, Cathryn; Demetri, George D et al. (2008) Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 26:626-32|
|Rocha-Lima, C M; Herndon 2nd, J E; Lee, M E et al. (2007) Phase II trial of irinotecan/gemcitabine as second-line therapy for relapsed and refractory small-cell lung cancer: Cancer and Leukemia Group B Study 39902. Ann Oncol 18:331-7|
|Lamont, Elizabeth B; Herndon 2nd, James E; Weeks, Jane C et al. (2006) Measuring disease-free survival and cancer relapse using Medicare claims from CALGB breast cancer trial participants (companion to 9344). J Natl Cancer Inst 98:1335-8|
|Halabi, Susan; Vogelzang, Nicholas J; Ou, San-San et al. (2006) Clinical outcomes by age in men with hormone refractory prostate cancer: a pooled analysis of 8 Cancer and Leukemia Group B (CALGB) studies. J Urol 176:81-6|
|Muss, Hyman B; Woolf, Susan; Berry, Donald et al. (2005) Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA 293:1073-81|
|Bogart, Jeffrey A; Herndon 2nd, James E; Lyss, Alan P et al. (2004) 70 Gy thoracic radiotherapy is feasible concurrent with chemotherapy for limited-stage small-cell lung cancer: analysis of Cancer and Leukemia Group B study 39808. Int J Radiat Oncol Biol Phys 59:460-8|
Showing the most recent 10 out of 18 publications